The European Commission (EC) has granted conditional marketing authorisation to bluebird bio鈥檚 gene therapy Zynteglo for the treatment of transfusion-dependent 尾-thalassemia (TDT).
Zynteglo is designed for patients aged 12 years and above that do not have a聽beta-thalassemia major (尾0/尾0) genotype and are able to undergo hematopoietic stem cell (HSC) transplantation. It will be used in cases where a human leukocyte antigen (HLA) matched HSC donor is not available.
TDT is a genetic disease that develops due to 尾-globin gene mutations characterised by reduced or absent haemoglobin. These patients require life-long blood transfusions to maintain haemoglobin levels.
However, such transfusions are associated with the risk of progressive multi-organ damage due to iron overload.
Zynteglo is intended to target the underlying genetic cause of the disease and help TDT patients without a 尾0/尾0聽genotype to become transfusion independent.
The drug adds functional copies of a modified form of the 尾-globin (尾A-T87Q-globin) into a patient鈥檚 own HSCs. This eliminates the need for donor HSCs.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn April this year, a European Medicines Agency (EMA) panel recommended Zynteglo for TDT treatment.
bluebird bio chief Nick Leschly said: 鈥淥ur first product approval is a humbling moment for all of us at bluebird, and we look forward to continuing our work with the TDT community and health systems to bring this important treatment to patients.鈥�
The EC’s authorisation is based on efficacy, safety and durability results obtained during the Phase I/II HGB-205 and the Phase I/II Northstar clinical trials.
It is further supported by findings from the ongoing Phase III Northstar-2 and Northstar-3 studies, as well as long-term follow-up trial LTF-303.
The HGB-205 data demonstrated transfusion independence in 75% of subjects that did not have a 尾0/尾0 genotype and were not receiving a transfusion for at least 12 months or more. Transfusion independence was maintained until data cut off for a duration of 21-56 months.
Non-serious study drug-related adverse events (AE) that occurred during the trials were hot flush, dyspnoea, abdominal pain, pain in the extremities and non-cardiac chest pain.
The company is collaborating with certain treatment centres with expertise in stem cell transplant and treating TDT patients to provide Zynteglo due to the technical and specialised nature of administering gene therapy in rare diseases.
